

# Carmen Guillen Ponce

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4116523/publications.pdf>

Version: 2024-02-01

130  
papers

2,797  
citations

218677  
26  
h-index

197818  
49  
g-index

140  
all docs

140  
docs citations

140  
times ranked

5070  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase I/II, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer. <i>European Journal of Cancer</i> , 2011, 47, 8-9.	2.8	453
2	Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. <i>Journal of Clinical Oncology</i> , 2016, 34, 2010-2019.	1.6	280
3	Circulating tumor cells (CTC) and KRAS mutant circulating free DNA (cfDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. <i>BMC Cancer</i> , 2015, 15, 797.	2.6	147
4	Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. <i>Anti-Cancer Drugs</i> , 2010, 21, S3-S11.	1.4	109
5	Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 853-861.	5.7	91
6	Refinement of screening for familial pancreatic cancer. <i>Gut</i> , 2016, 65, 1314-1321.	12.1	70
7	Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2. <i>Journal of Clinical Oncology</i> , 2019, 37, 230-238.	1.6	66
8	First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. <i>European Journal of Cancer</i> , 2018, 101, 263-272.	2.8	58
9	Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 1014-1022.	10.7	58
10	Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 221-232.	2.5	56
11	Reduced risk of pancreatic cancer associated with asthma and nasal allergies. <i>Gut</i> , 2017, 66, 314-322.	12.1	56
12	Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study. <i>Pancreatology</i> , 2019, 19, 64-72.	1.1	52
13	First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. <i>European Journal of Cancer</i> , 2015, 51, 1371-1380.	2.8	48
14	Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. <i>European Journal of Cancer</i> , 2015, 51, 942-949.	2.8	47
15	Comparison of two frailty screening tools in older women with early breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 51-64.	4.4	46
16	PanGen-Fam: Spanish registry of hereditary pancreatic cancer. <i>European Journal of Cancer</i> , 2015, 51, 1911-1917.	2.8	39
17	Muscle metastasis of carcinoma. <i>Clinical and Translational Oncology</i> , 2011, 13, 98-101.	2.4	38
18	Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5020-5027.	7.0	37

#	ARTICLE	IF	CITATIONS
19	Development of a cancer-specific Comprehensive Geriatric Assessment in a University Hospital in Spain. Critical Reviews in Oncology/Hematology, 2011, 77, 148-161.	4.4	34
20	FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and a circulating tumour cells: the randomised phase III VISN-1 trial. ESMO Open, 2020, 5, e000944.	4.5	32
21	Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence. Familial Cancer, 2013, 12, 767-777.	1.9	31
22	Use of geriatric assessment and screening tools of frailty in elderly patients with prostate cancer. Review. Aging Male, 2017, 20, 102-109.	1.9	30
23	Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain. Psycho-Oncology, 2018, 27, 1530-1537.	2.3	30
24	Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients. Clinical and Translational Oncology, 2020, 22, 457-467.	2.4	29
25	Gastric tumours in hereditary cancer syndromes: clinical features, molecular biology and strategies for prevention. Clinical and Translational Oncology, 2011, 13, 599-610.	2.4	28
26	Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer. Clinical and Translational Oncology, 2014, 16, 942-953.	2.4	28
27	Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Clinical and Translational Oncology, 2017, 19, 667-681.	2.4	27
28	Adjuvant Therapy of Resected Gastric Cancer Is Necessary. Seminars in Oncology, 2005, 32, 105-108.	2.2	26
29	EPCAM Germ Line Deletions as Causes of Lynch Syndrome in Spanish Patients. Journal of Molecular Diagnostics, 2010, 12, 765-770.	2.8	26
30	General recommendations paper on the management of older patients with cancer: the SEOM geriatric oncology task force's position statement. Clinical and Translational Oncology, 2018, 20, 1246-1251.	2.4	26
31	Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. , 2022, 10, e003255.		26
32	A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. Investigational New Drugs, 2017, 35, 634-641.	2.6	25
33	Can we avoid the toxicity of chemotherapy in elderly cancer patients?. Critical Reviews in Oncology/Hematology, 2018, 131, 16-23.	4.4	25
34	Overvaluation of the Vulnerable Elders Survey-13 As a Screening Tool for Vulnerability. Journal of Clinical Oncology, 2011, 29, 3201-3202.	1.6	24
35	Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers. PLoS ONE, 2018, 13, e0194844.	2.5	24
36	Circulating tumour cell analysis as an early marker for relapse in stage II and III colorectal cancer patients: a pilot study. Clinical and Translational Oncology, 2010, 12, 142-147.	2.4	23

#	ARTICLE	IF	CITATIONS
37	A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. <i>Annals of Oncology</i> , 2012, 23, 119-127.	1.2	23
38	CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 87-93.	2.5	22
39	Mammographic density and breast cancer in women from high risk families. <i>Breast Cancer Research</i> , 2015, 17, 93.	5.0	22
40	Novel Molecular Characterization of Colorectal Primary Tumors Based on miRNAs. <i>Cancers</i> , 2019, 11, 346.	3.7	22
41	A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk. <i>Annals of Oncology</i> , 2017, 28, 1618-1624.	1.2	20
42	Evofofosamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 193-193.	1.6	20
43	YOSEMITE: A 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus gemcitabine, paclitaxel protein-bound particles for injectable suspension and either 1 or 2 truncated courses of demcizumab (GAD). <i>Annals of Oncology</i> , 2017, 28, v211.	1.2	19
44	Current controversies in the management of metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 659-677.	2.3	17
45	Delphi consensus of an expert committee in oncogeriatrics regarding comprehensive geriatric assessment in seniors with cancer in Spain. <i>Journal of Geriatric Oncology</i> , 2018, 9, 337-345.	1.0	16
46	Identification of a novel BRCA1 large genomic rearrangement in a Spanish breast/ovarian cancer family. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 63-67.	2.5	15
47	Identification of gene expression profiling associated with erlotinib-related skin toxicity in pancreatic adenocarcinoma patients. <i>Toxicology and Applied Pharmacology</i> , 2016, 311, 113-116.	2.8	15
48	Gemcitabine+erlotinib versus gemcitabine+erlotinib+capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group. <i>European Journal of Cancer</i> , 2017, 75, 73-82.	2.8	15
49	Anti-VEGF therapy: a new approach to colorectal cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1385-1396.	2.4	14
50	The TGFBR1*6A allele is not associated with susceptibility to colorectal cancer in a Spanish population: a case-control study. <i>BMC Cancer</i> , 2009, 9, 193.	2.6	14
51	Biallelic MYH germline mutations as cause of Muir-Torre syndrome. <i>Familial Cancer</i> , 2010, 9, 151-154.	1.9	13
52	Clinical guideline seom: hereditary colorectal cancer. <i>Clinical and Translational Oncology</i> , 2015, 17, 962-971.	2.4	13
53	The Int7G24A variant of transforming growth factor-beta receptor type I is a risk factor for colorectal cancer in the male Spanish population: a case-control study. <i>BMC Cancer</i> , 2009, 9, 406.	2.6	12
54	Geriatric oncology in Spain: survey results and analysis of the current situation. <i>Clinical and Translational Oncology</i> , 2018, 20, 1087-1092.	2.4	12

#	ARTICLE	IF	CITATIONS
55	Diagnosis and current treatment of neurological paraneoplastic syndromes. Clinical and Translational Oncology, 2006, 8, 796-801.	2.4	11
56	Broad BRCA1 and BRCA2 mutational spectrum and high incidence of recurrent and novel mutations in the eastern Spain population. Breast Cancer Research and Treatment, 2010, 121, 257-260.	2.5	11
57	Diagnosis and staging of pancreatic ductal adenocarcinoma. Clinical and Translational Oncology, 2017, 19, 1205-1216.	2.4	11
58	SEOM clinical guideline on hereditary colorectal cancer (2019). Clinical and Translational Oncology, 2020, 22, 201-212.	2.4	11
59	Tumour location and efficacy of first-line EGFR inhibitors in wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials. ESMO Open, 2019, 4, e000599.	4.5	11
60	Extranodal Rosai-Dorfman Disease with Cutaneous and Periodontal Involvement: A Rare Presentation. Case Reports in Oncology, 2011, 4, 96-100.	0.7	10
61	Low prevalence of BRCA1 and BRCA2 mutations in the sporadic breast cancer of Spanish population. Familial Cancer, 2012, 11, 49-56.	1.9	10
62	Desensitizing oxaliplatin-induced fever: a case report. Journal of Investigational Allergology and Clinical Immunology, 2013, 23, 435-6.	1.3	10
63	Capecitabine plus oxaliplatin for the treatment of colorectal cancer. Expert Review of Anticancer Therapy, 2008, 8, 161-174.	2.4	9
64	Multidisciplinary management of locally advanced “borderline resectable adenocarcinoma of the head of the pancreas. Clinical and Translational Oncology, 2013, 15, 173-181.	2.4	9
65	Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?. Clinical and Translational Oncology, 2016, 18, 1072-1081.	2.4	9
66	Combination of KIR2DS4 and FcÎ³RIIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer. Scientific Reports, 2019, 9, 2589.	3.3	9
67	Sequential nab-paclitaxel/gemcitabine followed by modified FOLFOX for first-line metastatic pancreatic cancer: The SEQUENCE trial.. Journal of Clinical Oncology, 2022, 40, 4022-4022.	1.6	9
68	Tools For Decision-Making In Older Cancer Patients. Role Of The Comprehensive Geriatric Assessment. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 651-656.	1.7	8
69	Primary Hyperaldosteronism Associated with Vitiligo Vulgaris and Autoimmune Hypothyroidism. American Journal of the Medical Sciences, 2007, 333, 178-180.	1.1	7
70	Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results. European Journal of Cancer, 2020, 139, 51-58.	2.8	7
71	Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families of Eastern Spain. Breast Cancer Research and Treatment, 2008, 112, 69-73.	2.5	6
72	Follow-up recommendations and risk-reduction initiatives for Lynch syndrome. Expert Review of Anticancer Therapy, 2012, 12, 1359-1367.	2.4	6

#	ARTICLE	IF	CITATIONS
73	SEOM recommendations on the structure and operation of hereditary cancer genetic counseling units (HCGCUs). Clinical and Translational Oncology, 2013, 15, 20-25.	2.4	6
74	Oral Chemotherapy in Elderly Women with Metastatic Breast Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 665-672.	1.7	5
75	A revision on cryoglobulinaemia associated to neoplastic diseases. Clinical and Translational Oncology, 2007, 9, 229-236.	2.4	4
76	Targeted Anti-HER2 Cancer Therapy in Elderly Women Diagnosed with Breast Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 639-645.	1.7	4
77	Panhypopituitarism as first manifestation of a lung cancer. Clinical and Translational Oncology, 2007, 9, 53-55.	2.4	3
78	Multiple bone lesions resembling a metastatic origin. An unexpected diagnosis. Clinical and Translational Oncology, 2008, 10, 241-245.	2.4	3
79	Where Are We Headed With Research in Frail Elderly Patients With Cancer?. Journal of Clinical Oncology, 2016, 34, 4049-4050.	1.6	3
80	Relationship Between Sarcopenia and Frailty in a Spanish Cancer in the Elderly Unit: The ONCOSARCO Project. Journal of the American Medical Directors Association, 2016, 17, 760-761.	2.5	3
81	A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients with ECOG 2 advanced pancreatic cancer (PDAC). Annals of Oncology, 2017, 28, v212.	1.2	3
82	Patient with angina secondary to capecitabine. Clinical and Translational Oncology, 2005, 7, 335-335.	2.4	2
83	Resolution of pleural effusion in a IgD multiple myeloma after chemotherapy based on liposomal doxorubicin. Chinese-German Journal of Clinical Oncology, 2007, 6, 509-510.	0.1	2
84	TTD consensus document on the diagnosis and management of hereditary colorectal cancer. Clinical and Translational Oncology, 2010, 12, 356-366.	2.4	2
85	Relationship of BRCA1 and BRCA2 mutations with cancer burden in the family and tumor incidence. Familial Cancer, 2010, 9, 291-295.	1.9	2
86	Abstract CT177: A multi-center phase 2a trial of the CXCR4 inhibitor motixafortide (BL-8040) (M) in combination with pembrolizumab (P) and chemotherapy (C), in patients with metastatic pancreatic adenocarcinoma (mPDAC). Cancer Research, 2021, 81, CT177-CT177.	0.9	2
87	Gynecologic cancer screening in women at high risk of Lynch syndrome.. Journal of Clinical Oncology, 2011, 29, 1559-1559.	1.6	2
88	Deposition-associated diseases related with a monoclonal compound. Clinical and Translational Oncology, 2007, 9, 777-783.	2.4	1
89	Comment on "Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer". British Journal of Cancer, 2011, 104, 224-225.	6.4	1
90	Letter to the editor: "Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer". Investigational New Drugs, 2011, 29, 1515-1516.	2.6	1

#	ARTICLE	IF	CITATIONS
91	Panitumumab Plus FOLFOX4 or Panitumumab Plus Folfiri in Subjects with Wild-Type KRAS (EXON 2) Colorectal Cancer and Multiple or Unresectable Liver-Limited Metastases: Data from the Randomized, Phase II Planet Study. <i>Annals of Oncology</i> , 2014, 25, ii7.	1.2	1
92	2128 Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD). <i>European Journal of Cancer</i> , 2015, 51, S374-S375.	2.8	1
93	Impact of tumor location on the efficacy of first-line anti-EGFR monoclonal antibody plus chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC): Retrospective analyses of the randomized MACRO-2 and PLANET trials from TTD Group. <i>Annals of Oncology</i> , 2017, 28, v197-v198.	1.2	1
94	A pilot trial of PEGPH20 (Pegvorhialuronidase alfa) in combination with avelumab (anti-PD-L1) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 <i>Oncology</i> , 2018, 29, v51.	1.2	1
95	Ability of the Comprehensive Geriatric Assessment to Predict Frailty in Older People Diagnosed with Cancer in a General Hospital. <i>European Oncology and Haematology</i> , 2012, 08, 85.	0.0	1
96	Regorafenib as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC): A study of the Spanish Cooperative Group for digestive tumor therapy (TTD).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3651-TPS3651.	1.6	1
97	Preliminary safety results of regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD).. <i>Journal of Clinical Oncology</i> , 2015, 33, e14524-e14524.	1.6	1
98	Pathologic complete response (pCR) after neoadjuvant treatment in rectal cancer: Multi-institutional results in Spain.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15690-e15690.	1.6	1
99	Pulmonary thromboembolism in a breast cancer woman receiving anastrozole and prophylactic nadroparin. <i>Chinese-German Journal of Clinical Oncology</i> , 2007, 6, 507-508.	0.1	0
100	P38 Factors influencing overall survival in elderly women with early breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, S32.	4.4	0
101	Positron emission tomography in diagnosis of postradiotherapy dementia. <i>Journal of the Neurological Sciences</i> , 2009, 283, 299.	0.6	0
102	4028 POSTER Ability of the Comprehensive Geriatric Assessment to Predict Frailty in Elderly Patients Diagnosed With Cancer in a General Hospital. <i>European Journal of Cancer</i> , 2011, 47, S281-S282.	2.8	0
103	4032 POSTER Validation of the Barber Test as a Screening Questionnaire for Frailty In Elderly Patients. <i>European Journal of Cancer</i> , 2011, 47, S283.	2.8	0
104	6035 POSTER Characteristics of Individuals With High Scores in the Model PREMM1,2 Risk Assessment of Germline Mutations in MLH1 and MSH2. <i>European Journal of Cancer</i> , 2011, 47, S401.	2.8	0
105	Allocation of Physiologic Reserve Following Chemotherapy as a Marker of Frailty in Elderly Cancer Patients. <i>Annals of Oncology</i> , 2012, 23, ix459.	1.2	0
106	Journal Watch: Our expert panel highlights the most important research articles across the spectrum of topics relevant to the field of colorectal cancer. <i>Colorectal Cancer</i> , 2013, 2, 391-393.	0.8	0
107	Journal Watch: Our experts highlight the most important research articles across the spectrum of topics relevant to the field of colorectal cancer. <i>Colorectal Cancer</i> , 2013, 2, 109-111.	0.8	0
108	P-272 Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab. <i>Annals of Oncology</i> , 2015, 26, iv80.	1.2	0



#	ARTICLE	IF	CITATIONS
109	El cáncer hereditario en mujeres. Arbor, 2015, 191, a238.	0.3	0
110	P-081 Serum tumor markers as predictors of overall response rate and clinical benefit in patients with advanced esophagogastric adenocarcinoma (EGA) treated with chemotherapy. Annals of Oncology, 2015, 26, iv22.	1.2	0
111	Chemotherapy in frail elderly patients with metastatic castration-resistant prostate cancer?. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 579-580.	1.6	0
112	Predictive factors for early relapse and survival in resected pancreatic cancer: A single institution experience. Annals of Oncology, 2018, 29, v38.	1.2	0
113	Analysis of global factors associated with survival in esophageal squamous cell carcinoma: Our experience at Ramon y Cajal Hospital. Annals of Oncology, 2018, 29, v12-v13.	1.2	0
114	Multidimensional geriatric evaluation in elderly cancer patients and its relationship with age. Journal of Clinical Oncology, 2007, 25, 19651-19651.	1.6	0
115	Correlation between clinical-pathological parameters and family history to detect mutations in MLH1, MSH2, and MSH6.. Journal of Clinical Oncology, 2011, 29, 391-391.	1.6	0
116	Impact of colonoscopy screening on individuals at high risk of hereditary nonpolyposis colorectal cancer (HNPCC).. Journal of Clinical Oncology, 2011, 29, 384-384.	1.6	0
117	Genetic differences based on miRNAs of colorectal adenocarcinoma according to age and the presence or absence of MMR defect.. Journal of Clinical Oncology, 2012, 30, 495-495.	1.6	0
118	Spanish registry and screening program for families at high risk of pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2012, 30, 192-192.	1.6	0
119	Chemotherapy-induced changes in the physiologic reserve of elderly patients diagnosed with cancer.. Journal of Clinical Oncology, 2012, 30, e19590-e19590.	1.6	0
120	Endoscopic Ultrasonography in High-Risk Population for Pancreatic Cancer. Annals of Oncology, 2012, 23, ix472.	1.2	0
121	Imaging techniques in pancreatic cancer screening: Preliminary results from the PanGen-FAM registry.. Journal of Clinical Oncology, 2013, 31, 1529-1529.	1.6	0
122	Mammographic density and breast cancer in women from high-risk families.. Journal of Clinical Oncology, 2014, 32, 1525-1525.	1.6	0
123	Tumor markers as predictors of outcome in patients with advanced esophagogastric adenocarcinoma (EGA) treated with chemotherapy.. Journal of Clinical Oncology, 2015, 33, e15061-e15061.	1.6	0
124	KRAS mutant circulating free DNA (cfDNA) and circulating tumor cell (CTC) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.. Journal of Clinical Oncology, 2015, 33, e15252-e15252.	1.6	0
125	PANOVA: A pilot study of TTFelds concomitant with gemcitabine for front-line therapy of advanced pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2015, 33, e15269-e15269.	1.6	0
126	Rectal adenocarcinoma: Results of adjuvant chemotherapy in a retrospective cohort.. Journal of Clinical Oncology, 2015, 33, e14539-e14539.	1.6	0



#	ARTICLE	IF	CITATIONS
127	Kaposi sarcoma: A retrospective review.. Journal of Clinical Oncology, 2015, 33, e21520-e21520.	1.6	0
128	Rectal adenocarcinoma: Surveillance and timing of surgical resection after neoadjuvant chemoradiotherapy in a retrospective cohort.. Journal of Clinical Oncology, 2016, 34, 737-737.	1.6	0
129	Circulating biomarkers exploratory study in loco-regional gastroesophageal adenocarcinoma patients.. Journal of Clinical Oncology, 2016, 34, 17-17.	1.6	0
130	Abstract CT117: A phase II trial of TAK-264, a novel antibody-drug conjugate (ADC), in patients with pancreatic adenocarcinoma expressing guanylyl cyclase C (GCC). , 2016, , .		0